Moderna Inc (MRNA)

[axelvento]

Landmark Melanoma Vaccine Could Be Available in Just 2 Years

In a study involving 157 people with advanced melanoma, the Moderna vaccine in combination with Merck's immunotherapy drug Keytruda reduced the risk of recurrence or death by 49 percent over a period of three years, compared with Keytruda alone.

"We have one in two people, compared to the best product on the market, who survive," he said, "which in oncology is huge."

https://www.sciencealert.com/landmark-melanoma-vaccine-could-be-available-in-just-2-years